Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia? on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC) Current Hematologic Malignancy Reports ISSN 1558-8211 Curr Hematol Malig Rep DOI 10.1007/s11899-014-0242-1

1 23

Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media New York. This e-offprint is for personal use only and shall not be selfarchived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”.

1 23

Author's personal copy Curr Hematol Malig Rep DOI 10.1007/s11899-014-0242-1

CHRONIC LYMPHOCYTIC LEUKEMIAS (S O’BRIEN, SECTION EDITOR)

Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia? Peter Dreger & Emili Montserrat & on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC)

# Springer Science+Business Media New York 2015

Abstract Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (